<i>BRCA1/2</i> mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling.

J Gynecol Oncol · 2020 · PMC7189074 · PMID 31912679

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The time between breast and ovarian cancer diagnosis was longer in the BRCAm group than in the BRCAw group, although this difference did not reach statistical significance as well.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.